AU2003268180A8 - Compositions and methods of therapy for cancers characterized by expression of the tumor-associated antigen mn/ca ix - Google Patents

Compositions and methods of therapy for cancers characterized by expression of the tumor-associated antigen mn/ca ix

Info

Publication number
AU2003268180A8
AU2003268180A8 AU2003268180A AU2003268180A AU2003268180A8 AU 2003268180 A8 AU2003268180 A8 AU 2003268180A8 AU 2003268180 A AU2003268180 A AU 2003268180A AU 2003268180 A AU2003268180 A AU 2003268180A AU 2003268180 A8 AU2003268180 A8 AU 2003268180A8
Authority
AU
Australia
Prior art keywords
tumor
therapy
expression
compositions
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003268180A
Other versions
AU2003268180A1 (en
Inventor
Guita Lalehzadeh
Justin Wong
Robert Warne
Jill Winter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of AU2003268180A1 publication Critical patent/AU2003268180A1/en
Publication of AU2003268180A8 publication Critical patent/AU2003268180A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2003268180A 2002-08-23 2003-08-25 Compositions and methods of therapy for cancers characterized by expression of the tumor-associated antigen mn/ca ix Abandoned AU2003268180A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US40557702P 2002-08-23 2002-08-23
US60/405,577 2002-08-23
US64693403A 2003-08-22 2003-08-22
US10/646,934 2003-08-22
PCT/US2003/026612 WO2004017923A2 (en) 2002-08-23 2003-08-25 Compositions and methods of therapy for cancers characterized by expression of the tumor-associated antigen mn/ca ix

Publications (2)

Publication Number Publication Date
AU2003268180A1 AU2003268180A1 (en) 2004-03-11
AU2003268180A8 true AU2003268180A8 (en) 2004-03-11

Family

ID=31949897

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003268180A Abandoned AU2003268180A1 (en) 2002-08-23 2003-08-25 Compositions and methods of therapy for cancers characterized by expression of the tumor-associated antigen mn/ca ix

Country Status (5)

Country Link
EP (1) EP1576010A4 (en)
JP (1) JP2005536220A (en)
AU (1) AU2003268180A1 (en)
CA (1) CA2496572A1 (en)
WO (1) WO2004017923A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1487972T3 (en) 2002-02-21 2015-10-19 Inst Virology MN / CA IX-specific monoclonal antibodies generated from MN / CA IX-poor mice, as well as methods of use.
US7833734B2 (en) 2002-11-26 2010-11-16 Institute Of Virology Of The Slovak Academy Of Sciences CA IX-specific inhibitors
DOP2006000277A (en) * 2005-12-12 2007-08-31 Bayer Pharmaceuticals Corp ANTI MN ANTIBODIES AND METHODS FOR USE
WO2008091798A2 (en) * 2007-01-22 2008-07-31 Xencor, Inc. Optimized ca9 antibodies and methods of using the same
CA2708281A1 (en) * 2007-12-11 2009-08-27 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
US20220049012A1 (en) * 2019-05-06 2022-02-17 Navi Bio-Therapeutics, Llc Anti-carbonic anhydrase ix antibody

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5955075A (en) * 1992-03-11 1999-09-21 Institute Of Virology, Slovak Academy Of Sciences Method of inhibiting tumor growth using antibodies to MN protein
JP3910798B2 (en) * 1998-10-23 2007-04-25 インスティトゥート オブ ヴァイロロジー MN gene and protein

Also Published As

Publication number Publication date
CA2496572A1 (en) 2004-03-04
AU2003268180A1 (en) 2004-03-11
EP1576010A4 (en) 2006-12-27
JP2005536220A (en) 2005-12-02
EP1576010A2 (en) 2005-09-21
WO2004017923A2 (en) 2004-03-04
WO2004017923A3 (en) 2005-07-14

Similar Documents

Publication Publication Date Title
AU2003302892A8 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
EP1515982A4 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
EP1571968A4 (en) Compositions and methods for the diagnosis and treatment of tumor
EP1589933A4 (en) Compositions and methods for the diagnosis and treatment of tumor
AU2003293194A8 (en) Compositions and methods for treating prostate cancer
AU2001265296A1 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
EP1571968A3 (en) Compositions and methods for the diagnosis and treatment of tumor
EP1572091A4 (en) Compositions and methods for the diagnosis and treatment of tumor
EP1578996A4 (en) Compositions and methods for the diagnosis and treatment of tumor
EP1553912A4 (en) Compositions and methods for the diagnosis and treatment of tumor
AU2003224076A1 (en) Antibody combination useful for tumor therapy
EP1575571A4 (en) Compositions and methods for the diagnosis and treatment of tumor
EP1468118A4 (en) Methods and compositions for treating cancer
EP1551388A4 (en) Compounds useful for the treatment of cancer, compositions thereof and methods therewith
EP1349485A4 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
PL368035A1 (en) Compositions and methods for the treatment of cancer
AU2003219160A1 (en) Methods and compositions for the treatment of cancer
AU3483001A (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
AU2003268180A8 (en) Compositions and methods of therapy for cancers characterized by expression of the tumor-associated antigen mn/ca ix
AU2003230849A8 (en) Compositions and methods for the therapy and diagnosis of lung cancer
AU2001249493A1 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
EP1587405A4 (en) Novel compositions and methods for cancer
AU2003298708A8 (en) Gpc99 and gpc99a: methods and compositions for treating cancer
EP1684795A4 (en) Methods and agents for the treatment of cancer
AU2003293665A8 (en) Compositions and methods for treating cancer using cytotoxic cd44 antibody immunoconjugates and radiotherapy

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase